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ABSTRACT
Cancer immunotherapy has been revolutionised by drugs that enhance the ability 
of the immune system to detect and fight tumors. Immune checkpoint therapies that 
target the programmed death-1 receptor (PD-1), or its ligand (PD-L1) have shown 
unprecedented rates of durable clinical responses in patients with various cancer 
types. However, there is still a large fraction of patients that do not respond to 
checkpoint inhibitors, and the challenge remains to find cellular and molecular cues 
that could predict which patients would benefit from these therapies. Using a series 
of qualitative and quantitative methods we show here that PBMCs and platelets from 
smokers and patients with head and neck squamous cell carcinoma (HNSCC) or lung 
cancer express and up-regulate PD-L1 independently of tumor stage. Furthermore, 
treatment with Atezolizumab, a fully humanised monoclonal antibody against PD-L1, 
in 4 patients with lung cancer caused a decrease in PD-L1 expression in platelets, 
which was restored over 20 days. Altogether, our findings reveal the expression of 
the main therapeutic target in current checkpoint therapies in human platelets and 
highlight their potential as biomarkers to predict successful therapeutic outcomes.
INTRODUCTION
The tumor microenvironment is remarkably 
immunosuppressive. Many tumors evade immune cell 
attack by expressing signalling molecules that trigger fail-
safe mechanisms, normally involved in the regulation of 
uncontrolled inflammation, or autoimmune responses. 
For example, tumors express programmed death-ligand 1 
(PD-L1) which binds to the immune checkpoint protein 
programmed cell death protein 1 (PD-1) expressed on 
antigen-specific CD8(+) T cells. Binding of tumor-derived 
PD-L1 to PD-1 limits the host immune response essentially 
by switching off T cells that would normally attack cancer 
cells. Checkpoint inhibition therapies decouple the PD-1/
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PD-L1 pairing and release the molecular brakes off T 
cells, to unleash them on tumors [1].
Checkpoint inhibitors have shown unprecedented 
rates of durable clinical responses in patients with various 
cancer types, and have now moved to the forefront of 
cancer research. Since March 2015, several checkpoint 
inhibitors were granted approval by the US Food and 
Drug Administration (FDA) to treat a variety of cancers. 
However, many clinical trials suggest that only a few 
types of cancer respond to checkpoint inhibition, and only 
a fraction of patients who are eligible for treatment with 
checkpoint inhibitors respond to therapy. In most solid 
cancers only about a third of the patients respond with a 
prolonged overall survival.
The reasons why some patients respond to PD-L1 
blockage, while others do not, are not fully understood. 
The expression of PD-L1 by cancer cells [2], the quality 
of T cells circulating in the blood [3], and that infiltrate 
tumors [4], the mutational rate of cancer cells [5], as well 
as defects on DNA repair [6], the sensitivity to immune 
effectors [7], and even the presence of specific microbes 
in the gut [8-10] have all been associated with improved 
response to checkpoint inhibitors. With increasing 
understanding of various cell-to-cell interactions [11] the 
hunt is on for reliable biological markers (biomarkers) 
that could effectively flag people who are most likely to 
benefit from individualized cancer immunotherapy [12].
Hence, identifying tumor or host immune cells 
that express PD-L1, which set the brakes on T cells, 
might help to improve the efficacy of immunecheckpoint 
therapies or indicate novel therapeutic targets. Importantly, 
although the expression of PD-L1 in tumors may be used 
as indicators of clinical response, blood-based profiling 
to understand the mechanisms of PD-1 blockade remains 
poorly explored. Inspired by this, we performed PD-L1 
staining in peripheral blood mononucleated cells (PBMCs) 
from a cohort of patients with head and neck squamous 
cell carcinoma (HNSCC). Using flow cytometry, two-
photon microscopy and luminex multiplex cytokine arrays, 
we report here that blood circulating platelets isolated 
from HNSCC patients up-regulate PD-L1, while PD-L1 
is only marginally expressed by platelets from healthy 
donors. Importantly, cigarette smoking, a key risk factor 
for HNSCC and lung cancer, was sufficient to up-regulate 
PD-L1 expression in platelets from cancer-free smokers. 
Furthermore, we observed that platelet-derived PD-L1 
(pPD-L1) is directly affected by Atezolizumab, an anti-
PD-L1 based therapy. Treatment of lung cancer patients 
with the PD-L1 inhibitor atezolizumab caused a decrease 
of PD-L1 in platelets and PBMCs, without affecting whole 
platelet counts or white blood cell counts. Our data suggest 
that rather than being bystander cell fragments, platelets 
may have active roles in cancer immunotherapy through 
their expression of PD-L1. The functional significance and 
predictive value of pPD-L1 for PD-L1 therapies warrants 
further investigations.
RESULTS
Increased PD-L1 expression on PBMCs in 
peripheral blood of HNSCC patients
In many solid cancers the expression of PD-L1 on 
tumors has been associated with better response to PD1 
and PD-L1 immunotherapy [14]. However, assessment of 
PD-L1 expression in less invasive blood-based sampling 
has not been explored widely. Therefore, we assessed PD-
L1 fluorescence on PBMCs isolated from healthy donors, 
or HNSCC patients in different stages of the disease. 
HNSCC patients were stratified according to their disease 
status: metastatic (N+), or non-metastatic (N-), based 
on the occurrence of lymph node metastasis, as well as 
primary, or recurrent tumors. To evaluate the predictive 
capacity of PD-L1 on immune cells for the development 
of HNSCC, we assessed the expression of PD-L1 in 
PBMCs from patients with smoking habits. Smoking is the 
number one risk-factor for the development of HNSCC, 
and has also been associated with increased production 
of interferon-gamma (IFN-g) [15] a key cytokine that 
enhances PD-L1 expression in immune cells [16].
In agreement with previous observations [17], PD-
L1 expression was increased in circulating immune cells of 
HNSCC patients, irrespectively of their metastatic status 
(Figure 1A). HNSCC patients (N+ and N-) were further 
stratified according to the incidence of tumors, as primary 
and recurrent cancers (Figure 1B). PD-L1 was similarly 
expressed on PBMCs from these patients irrespectively of 
their tumor incidence. Those data suggest that the presence 
of locoregional or distant metastases did not influence the 
quantity of PD-L1 expression on immune cells.
The PBMC fraction is comprised of different 
immune cells which express PD-L1 [18]. To locally 
associate PD-L1 expression in the PBMC population, 
we performed two-photon fluorescence microscopy 
(TPEF) in cytopsin slides containing fixed PBMCs from 
healthy donors or HNSCC patients. TPEF imaging of 
PBMCs from these patients revealed the presence of a 
large quantity of platelets, which surprisingly, were also 
found to express PD-L1 (Figure 1C). Importantly, platelets 
present in PBMC preparations from healthy donors, were 
mostly negative for PD-L1 (Figure 1C). Although PD-L1 
has been reported on immune cells [16], these findings are 
unprecedented as there are no reports of its expression on 
human platelets. Thus, we investigated more closely the 
expression of platelet PD-L1 (pPD-L1) in HNSCC cancer.
In the same HNSCC cohort as above we examined 
the expression of PD-L1 in cells from the tumors, or in 
the immune cells recovered from solid tumors (tumor 
infiltrating cells). Most samples expressed PD-L1 on 
very low levels within both cell populations (around 1%). 
No correlations were found between PD-L1 expression 
in the tumor, or on tumor infiltrating cells and PD-L1 in 
peripheral blood cells (data not shown).
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Increased PD-L1 expression on purified platelets 
from HNSCC patients
Next, we employed different methods to assess 
the dynamics of PD-L1 expression in highly purified 
platelets from healthy donors and HNSCC patients. For 
this, platelets were purified from peripheral blood (see 
methods) and their purity was assessed using leukocyte 
(CD45) and platelet markers (CD41), as well as matching 
isotype controls. Flow cytometric assessment revealed that 
platelet preparations were mostly free of contaminating 
leukocytes (Figure 2A and 2B). Then, we assessed the 
protein expression of PD-L1 on the surface of platelets 
from healthy donors (HDs), or HNSCC patients by flow 
cytometry. PBMCs from the same donors were used as 
comparison. We found a significant increase in PD-L1 
on platelets and PBMCs of HNSCC patients compared 
to healthy donors (Figure 2C-2D). These fluorescence 
measurements were further confirmed by a luminex 
cytokine plex performed on whole cell lysates of PBMCs 
and purified platelets from HNSCC patients (Figure 2E). 
In line with what we observed with PBMCs (Figure 1), 
PD-L1 was similarly expressed on platelets isolated 
from HNSCC patients that were stratified based on 
the incidence of their tumors, or their metastatic stage 
(Figure 2F).
Figure 1: PD-L1 is up-regulated in blood immune cells and platelets of HNSCC patients. (A) Flow cytometric quantification 
of % of PD-L1 fluorescence in PBMCs isolated from healthy donors (HDs, n = 6), smokers (n = 12), and HNSCC patients with (N+, 
n = 16), or without (N-, n = 7) lymph node metastasis. Statistical analysis was performed by Ordinary one-way ANOVA, Tukey’s multiple 
comparisons test. **** p < 0.0001. (B) N+ and N- HNSCC patients in (A) were further stratified accordingly to the tumor incidence as 
primary, or recurrent cancer. Graphs show the % of PD-L1 fluorescence in PBMCs in relation to tumor incidence. Unpaired t test was used 
to calculate the differences. n.s. p = 0.9230. (C) Top: Two-photon microscopy (TPEF) imaging of cytospin slides containing PBMCs from 
a HNSCC patient stained with the platelet marker CD41. Nuclei were stained with (DAPI). Bottom: TPEF imaging of PD-L1 and CD41 
staining on cytospin slides containing PBMCs from a healthy donor, or a HNSCC patient, showing PD-L1 expression on platelets (CD41+ 
cells). Data is representative of 10 different experiments.
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pPD-L1 is affected by treatment with the 
immune check-point inhibitor atezolizumab
Next, we speculated that expression of PD-L1 on 
platelets might render them susceptible targets of antibody-
based anti PD-L1 therapies. Indeed, thrombocytopenia 
is a fairly common side-effect of immune checkpoint 
inhibitors [19]. And, recently, two cancer drug trials were 
paused after evidences of bleeding disorders in patients 
receiving anti-PDL-1 therapy (Kestrell Study - https://
uk.reuters.com/article/us-astrazeneca-cancer/astrazeneca-
pauses-two-cancer-drug-trials-enrolment-due-to-bleeding-
idUKKCN12R2D4). To investigate this hypothesis, 
we assessed total platelet counts and PD-L1 expression 
in platelets purified from lung cancer patients (n = 4) 
before and several days after treatment with the PD-L1 
targeting antibody Atezolizumab in a routine clinical 
application. Lung cancer patients received a flat dose of 
1200 mg atezolizumab in a 3-week regimen. The therapy 
was well tolerated. Besides routine control of white blood 
cell counts (WBCs) the values of PD-L1 expressing cells 
were monitored throughout therapy. Assessments of PD-
L1 expression on PBMCs and blood purified platelets 
revealed that while atezolizumab did not significantly 
Figure 2: PD-L1 is upregulated in blood platelets from HNSCC patients. (A) Flow cytometric analysis showing the scatter 
characteristics and the gating strategy to assess the purity of platelets. Data is representative of >30 independent experiments with different donors. 
(B) Cells were further gated by their expression of the leukocyte (CD45) and platelet (CD41) markers, compared to staining with IgG matched 
isotype controls. Data shows two representative healthy donors (HD) and HNSCC patients. (C) Representative histogram of the fluorescence of 
PD-L1, or an IgG matched isotype control, on PBMCs and platelets isolated from a HD, and a HNSCC patient. (D) Cummulative percentages of 
PD-L1 on PBMCs, and platelets (PD-L1+CD41+) isolated from HDs (n = 6, same as in Figure 1A), and HNSCC patients (n = 37). (E) Luminex 
Cytokine Array comparing PD-L1 levels in PBMCs and platelets isolated from HDs (n = 8) and HNSCC patients (n = 14). Statistical differences 
were calculated using Unpaired T test. P values are indicated. (F) Flow cytometric quantification of % of PD-L1 fluorescence in purified platelets 
from healthy donors (HDs, n = 6), smokers (n = 12), and HNSCC patients with (N+, n = 16), or without (N-, n = 7) lymph node metastasis. 
Statistical analysis was performed by Kruskal-Wallis, Dunn’s multiple comparisons test. * p < 0.05. (G) N+ and N- HNSCC patients in F were 
further stratified accordingly to the tumor incidence as primary or recurrent cancer. Graphs show the % of PD-L1 fluorescence in purified platelets 
in relation to tumor incidence. Mann-Whitney test was used to calculate the differences. n.s. P values are indicated.
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affect the PD-L1 expression on PBMCs (Figure 3A 
and 3B), the amount of PD-L1 expressing platelets 
diminished in the blood of treated patients in the first 7 
days of therapy (Figure 3B). Importantly, atezolizumab 
did not significantly affect the clinical total platelet or 
white blood cell count (Figure 3C), suggesting that PD-
L1 inhibition did not affect free platelets, but might have 
targeted platelets complexed to immune cells. PD-L1 
expression on PBMCs and platelets were reconstituted 
after 21 days of therapy, consistent with the beginning of 
the next atezolizumab cycle. Altogether, our data indicate 
that blood platelets are a dynamic source of PD-L1, which 
may have potential effects on cancer immunotherapy.
After 3 cycles of therapy, a follow up examination by 
CT scan revealed no increase in tumor burden, but rather a 
slight regression. Although atezulizumab therapy was halted 
in one patient due to occurence of severe allergic reactions, 
this patient showed a stable disease after 3 cycles of therapy.
Our findings indicate that anti-PD-L1 therapy 
targets PD-L1 expressed on platelets. This observation 
could potentially arise from competition for epitope 
binging between Atezolizumab and our PE-labeled 
anti-PD-L1 antibody. To exclude this possibility, 
we purified platelets from a HNSCC patient and 
incubated them ex-vivo with clinical concentrations 
of Atezolizumab (as well as 10 fold higher dosages). 
Atezolizumab treated platelets were then co-stained 
with the anti-PD-L1 used in our study. Importantly, 
pre-incubation of freshly isolated HNSCC platelets 
with Atezolizumab did not influence the staining of 
PD-L1 in vitro (Data not shown). Furthermore, PD-L1 
expression was not affected on PBMCs before vs after 
therapy. Altogether, these findings indicate that epitope 
binding competivity does not account for the observed 
effects of Atezolizumab on PD-L1 expression in treated 
patients.
Figure 3: PD-L1 in platelets and PBMCs is affected by atezolizumab. (A) Flow cytometric assessment of the percentages of 
PD-L1 fluorescence in PBMCs, or platelets (gated on CD41+PD-L1+ events) of lung cancer patients (n = 4) before (day 0) or at 1, 7 and 21 
days after therapy with 1,200 mg of atezolizumab. (B) Luminex Cytokine Array comparing PD-L1 levels in PBMCs and purified platelets 
from lung cancer patients before and after several days post therapy as in A. (C) Total leukocyte and platelet counts in peripheral blood 
of lung cancer patients before (day 0) or at 1, 7 and 21 days after therapy. Differences were calculated using Ordinary one-way ANOVA, 
Tukey’s multiple comparisons test.
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DISCUSSION
A long-standing question in cancer immunotherapy 
is how to identify the most suitable patients that would 
benefit from immune checkpoint inhibitors. Despite the 
successes of checkpoint inhibitors in several cancers, 
including HNSCC [20, 21], there are still a substantial 
proportion of patients that do not respond to therapy. 
Hence, considerable research efforts are now directed to 
identify routinely available blood and clinical markers 
that may predict response to therapy. Our study provides 
the first report of PD-L1 expression in circulating blood 
platelets and introduces them as potentially novel and 
non-invasive biomarkers in head and neck squamous cell 
carcinoma (HNSCC), with yet unexplored implications 
for checkpoint inhibition therapies. These observations 
were also extended to other cancer types, as we also found 
increased PD-L1 expression on platelets from patients 
with lung cancer. In our patient cohort, PD-L1 expression 
was not correlated with disease stage, the occurence of 
lymph node metastasis, or with the incidence of the tumor 
(primary vs recurrent). Indeed, platelet-PD-L1 (pPD-L1) 
levels were comparably high in all cancer cases compared 
to healthy donors. Interestingly, we found that cancer-free 
individuals with smoking habits displayed an intermediate 
phenotype, with significantly higher PD-L1 expression in 
both PBMCs and purified platelets, compared to healthy 
donors.
The presence of infiltrating immune cells, mainly 
CD8+ T cells, both at the invasive tumor margin and 
inside tumors is an essential element to predict better 
responses to immune checkpoint therapies [4]. The core 
of solid tumors is not easily assessed by immune cells, 
and the few infiltrating immune cells that gain access, 
must battle this immunosuppressive environment to kill 
the target cancer cells. PD-L1 expression on immune 
cells infiltrating the HNSCC are thought to be favorable 
prognostic factors for resected HNSCC, highlighting the 
importance to distinguish between PD-L1 expression 
on tumor cells (TC) and tumor-infiltrating immune 
cells (IC) [17]. We have found that the elevated PD-L1 
expression in the peripheral blood did not correlate with 
the PD-L1 expression within the tumor environment, or 
in the immune cells recovered on from the tumor. This 
might explain previous reports of better response to 
check point inhibitors in patients with low or negative 
PD-L1 expression in tumors. PD-L1 expression in 
the peripheral blood might be a determining factor to 
predict the outcome of check-point immunotherapy. In 
this context, platelets arise as potential immune players 
in cancer therapy. There are approximately one trillion 
platelets circulating in the blood of a healthy adult (150 
- 400 x 109/L). These cells permeate through the small 
capillary vessels, and can reach deep areas in the tissues, 
including the core of a tumor, which is usually refractory 
to most immune cells. Tumor infiltrating platelets can 
incorporate tumor-associated molecules, a phenomenon 
known as “education”, and convey accurate information 
about cancer signatures [22, 23]. Indeed, this and other 
features of platelets have been successfully employed as 
biomarkers for early detection of tumors [24, 25]. The 
close interactions of platelets and cancer cells is rapidly 
becoming a fruitful area of scientific investigation and is 
currently being explored therapeutically. A recent study 
conjugated anti-PD-1 engineered monoclonal antibodies 
to the surface of platelets, which were used to deliver 
anti-PD-1 therapies directly into tumors. In a pre-clinical 
model of melanoma, platelet activation caused effective 
release of anti-PDL1 by platelet-derived microparticles 
and prolonged survival after surgery by reducing the risk 
of cancer regrowth and metastatic spread [24, 25]. On the 
other hand, platelets have also been involved in tumor 
metastasis by different mechanisms [26]. Platelet-derived 
TGFβ and direct platelet-tumor cell contacts mediate the 
transition of cancer cells into an invasive mesenchymal-
like phenotype and enhanced metastasis in vivo [27]. 
Platelets were also reported to shield circulating tumor 
cells from recognition through the immune system [28].
Importantly, we found that PD-L1 expression is up-
regulated in platelets and PBMCs independently of tumor 
stage (N-, stage I and II; N+ stage III and IV), and is 
already enhanced in platelets and PBMCs from smokers, 
which are under increased risk to develop HNSCC or 
lung cancer. These findings imply that pPD-L1 may have 
powerful predictive power and, as previously reported 
[22], could be an useful biomarker for early stage cancers. 
The expression of PD-L1 on platelets from cancer patients 
also raises the possibility that pPD-L1 could interfere with 
immune checkpoint therapies, likely by competing with 
therapeutic antibodies directed against PD-L1 on cancer 
cells. This hypothesis, though not tested experimentally, 
is supported by observations that high platelet counts are 
associated with poor prognosis in several types of cancers 
[29], and were reported to impair the response to primary 
tyrosine kinase inhibitor therapy for metastatic renal cell 
carcinoma [30].
The use of liquid biopsies for the monitoring 
of checkpoint relevant drugs is completely new and 
unexplored. Our findings show that whole blood counts 
(WBCs, Figure 3C) are not influenced by atezolizumab 
therapy and therefore are not reliable to assess clinical 
response to immune checkpoint therapy. With the 
search for blood-based biomarkers on the rise, our study 
highlights the importance of considering platelets for the 
assessment of PD-L1 expression, which would also help 
to select patients suitable for PD-1 therapies. The FDA has 
set high levels of PD-L1 expression in the primary cancer 
tissue as a criterion for treatment with Pembrolizumab, 
a PD-1 blocking antibody, for certain cancers, e.g. lung 
cancer. Furthermore, insurance companies rely on the 
percentage of PD-L1 expression in the primary cancer 
to include patients and cover expenses of clinical 
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treatment with PD1 or PDL1 inhibitors. In HNSCC PD-
L1 expression in cancer tissue shows only modest utility 
in predicting such benefit. Many HNSCC patients that 
experienced a partial or complete remission displayed a 
mere 10% positivity of PD-L1, some of them were even 
PD-L1 negative before therapy [21]. We hope that new 
studies with larger cohorts will validate and correlate 
the pPD-L1 with clinical response rates. If pPD-L1 
has biomarker potential, it could also help to make 
personalised therapy easier, and change the current flat 
dose regimen (where equal doses are administered to all 
patient) to a more individualised concept based on, platelet 
counts, and pPD-L1 levels in the blood.
Study limitations
Although we could sucessfully purify blood platelets 
from most contaminating leukocytes, the PBMC fraction 
was largely contaminated with platelets. Thus, it is not yet 
possible to account for how much of the PD-L1 expression 
detected on PBMCs is derived from complexed platelets.
Furthermore, although we observed decreased PD-
L1 expression on platelets from patients treated with 
atezolizumab, the therapy did not affect whole platelet 
blood counts. Two possible reasons for these findings are: 
i) Atezolizumab targets PD-L1 on platelets complexed to 
immune cells, which are not included on total platelets 
counts assessed with automatic whole blood counters. ii) 
The low sample size (n = 4) of the cohort for before vs 
after atezolizumab.
Our study also raises new questions: what are the 
mechanisms that drive the up-regulation of PD-L1 in 
circulating blood platelets? Are platelets educated at the 
tumor site to up-regulate pPD-L1, or do tumors secrete 
factors that induce megakaryocytes to release platelets 
containing pPD-L1? These hypotheses need further 
experimental validation. For example, immunoprotein 
profiling of megakaryocytes from HNSCC patients, 
or incubation of megakaryocytic cell lines with tumor 
conditioned medium will aid in the investigations.
Furthermore, what are the functions of PD-
L1 expressing platelets in tumor development, or in 
immunotherapy? Finally, the suitability of pPD-L1 as a 
general tumor biomarker still warrants investigations in 
larger cohorts and in different cancer types.
MATERIALS AND METHODS
Patients characteristics
This study was approved by the ethics committee of 
the University of Lübeck (Az16-278/2017). All patients 
enrolled have signed an informed written consent, and 
were educated about the aims of the study and the use of 
their samples. Blood samples were collected from healthy 
donors (n=8), healthy voluntaring smokers (n=12), head 
and neck squamous cell carcinoma (HNSCC) patients 
from all anatomical regions (HNSCC stage I:4; stage II: 
2; stage III 7, stage IV:17) and lung cancer patients (stage 
IV:4). All patients were selected randomly from July to 
December 2017 and received a routine clinical workup for 
diagnosis and guideline adapted treatment. Blood samples 
were drawn prior to therapy. Tumor stage was evaluated 
for every patient by CT scans and clinical examination.
Atezolizumab treatment regime
According to new treatment standards, the four 
patients with lung cancer were treated with Atezolizumab 
(trade name Tecentriq) a fully humanized, engineered 
monoclonal antibody of IgG1 isotype against the protein 
programmed cell death-ligand 1 (PD-L1). All four patients 
received 1200 mg i.v. flat dose in a three weekly regimen. 
Clinically therapy was tolerated very well by all four 
patients without relevant side effects.
Platelet and PBMC isolation from human blood
Human platelets were isolated essentially as previously 
described [13], with slight modifications. In brief, venous 
blood was drawn into S-Monovette® 9NC collection tubes. 
The blood was centrifuged for 5 minutes at 330g without 
brake to obtain platelet-rich plasma (PRP). All following 
centrifugation steps were performed without brake and in the 
presence of 200nM PGE1 to inhibit platelet activation. PRP 
was transferred to a new tube and diluted 1:1 with phosphate-
buffered saline (PBS) to reduce leukocyte contamination and 
centrifuged for 10 minutes at 240 x g. Platelets were pelleted 
by centrifugation at 430 x g for 15 minutes and washed once 
with PBS, before they were lysed in RIPA buffer (1% Igepal 
CA-630, 0.5% Natrium Deoxycholat, 0.1% SDS in 1x PBS). 
PBMCs were isolated from the remaining blood fraction 
after taking off the PRP by density gradient centrifugation 
in Ficoll-Paque PLUS. After washing the PBMCs twice with 
PBS, cells were also lysed in RIPA buffer containing protease 
and phosphatase inhibitors. The purity of the isolated platelets 
and PBMCs was assessed by flow cytometry using CD45 
(leukocyte) and CD41a (platelet) markers.
Purity assessment of the isolated cells by flow 
cytometry
Samples of isolated platelets and PBMCs were 
analysed for purity after each experiment. Cells were 
blocked with 1:10 human Fc blocking reagent for 10 
minutes at room temperature (RT) before samples were 
stained with fluorochrome-conjugated monoclonal anti-
human Ig antibodies against CD41a and CD45 for 30 
minutes in the dark. Cells were washed and resuspended 
in flow cytometry buffer (1% FCS in PBS) for analysis. 
Compensation beads (OneComp eBeads) and isotype 
controls were prepared in the same way. Cell viability 
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was confirmed using by Annexin V and propidium iodide 
staining (BD Biosciences, Heidelberg, Germany). Flow 
cytometry was performed with a FACS Canto A flow 
cytometer and data were analysed using FACS Diva 
software 6.0 (BD Biosciences, Heidelberg, Germany) 
and the FlowJo software (Tree Star). The applied gating 
strategy was based on doublet discrimination and isotype-
matched control antibodies.
Cytospins of PBMC/Immunohistochemistry
Peripheral Blood (7.5 mL) was mixed with equal 
volume of ice-cold PBS and carefully transferred onto 
a 15 ml layer of cold Ficoll-solution. and centrifuged 
at 15 °C for 20 min at 800 × g. The upper plasma layer 
was carefully removed and discarded. The interphase 
(containing PBMCs) was transferred into a fresh 50-ml 
tube. Cold PBS was added to a total volume of 25 mL 
and samples were centrifuged at 4 °C for 5 min at 300 × 
g. The supernatant was discarded and cells resuspended 
in PBS. PBMC cytospins were prepared using 100 μL of 
cell suspension, which was centrifuged in a cytofuge for 
4 min at 800 rpm. Cytospins were air-dried in the dark 
overnight. Slides were covered with 20% acetone for 
10 minutes for fixation and permeabilization, followed 
by incubation with the specific primary antibodies anti-
CD41 and anti-PD-L1, or IgG matched isotope controls 
over night at 4°C. After washing with PBS the secondary 
antibodies goat anti-rabbit Cy3 and goat anti-rabbit FITC 
were incubated for 45 min, respectively. The slides were 
rinsed three times in PBS. Nuclei were stained with DAPI 
(1 μg/mL, Roche Diagnostics, Mannheim, Germany). The 
samples were rinsed three times for 5 minutes in PBS and 
embedded in Fluoromount G (Southern Biotechnologies 
Associates, Birmingham, Alabama, USA). Samples were 
imaged using Two-photon microscopy (TPEF).
List of reagents
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-human CD41a FITC (HIP8) eBioscience Cat#11-0419-42
Anti-human CD45 PE (2D1) eBioscience Cat#12-9459-42
Anti-human PD-L1 PE Biolegend Cat#329706
Anti-human CD41 Biolegend Cat#303704
Anti-human PD-L1 Abcam Cat#ab58810
donkey anti rabbit Cy3 secondary antibody Invitrogen Cat#A21206
goat anti rabbit FITC secondary antibody Jackson ImmunoRes Cat#111-165-003
FcR Blocking Reagent, human Miltenyi Biotech Cat#130-059-901
OneComp eBeads eBioscience Cat#01-1111-42
Chemicals, Peptides and Recombinant Proteins
Ficoll-Paque PLUS GE Healthcare Cat#17-1440-03
GibcoTM RPMI 1640 Medium Thermo Fisher Cat#21875091
GibcoTM Dulbecco’s Phosphate Buffered Saline (PBS) Thermo Fisher Cat#14190144
Fetal Calf Serum (FCS) Invitrogen
Prostaglandin E1 (PGE-1) Sigma-Aldrich Cat#P5515-1MG
Critical Commercial Assays
S-Monovette 9NC tubes Sarstedt Cat#01.1606.001
Immuno-Oncology Checkpoint 14-Plex Human 
ProcartaPlex™ Panel 1 ThermoFisher Scientific EPX14A-15803-901
Software and Algorithms
GraphPad Prism 7 GraphPad N/A
FlowJo 10.4 FlowJo N/A
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Luminex multiplex cytokine measurements
Multi-cytokines in platelet and PBMC lysates were 
measured with an Immuno-Oncology Checkpoint 14-
plex ProcartaPlexTM bead assay from ThermoFisher and 
measured on a MAGPIX instrument using Luminex xMAP 
Technology. The analysis was performed according to the 
manufacturer’s instructions with slight modifications. The 
standard stock vial was diluted in 900μl in total and a 1:2 
dilution series was used in the assay. Similarly, 200 μL of 
samples and standard were loaded onto the 96-well plate 
before overnight incubation at 4°C. Results were analyzed 
using GraphPad Prism Version 7.0f.
IHC staining for PD-L1 in HNSCC tumors
The tissue samples were formalin-fixed and 
paraffin embedded (FFPE) (4% buffered formalin, BÜFA, 
Hude, Germany; Paraffin, Leica Microsystems, Wetzlar, 
Germany). 4 μm thick slices were cut off from the 
paraffin blocks by microtome and placed on Super Frost 
glass slides (Menzel, Braunschweig, Germany). To verify 
staining success a positive control tissue (placenta) was 
placed on each slide.
Immunohistochemistry (IHC) was performed 
using an automated staining platform (Ventana, Roche, 
Tuscon AZ, USA). We used the E1L3N clone of PD-L1 
manufactured by Cell Signalling (Danvers MA, USA,). It 
was diluted 1:50 and pretreated by Tris-EDTA (pH 8,4, 
Ventana). An OptiView HRP Detection Kit (Ventana) were 
used according to the manifacturer’s instructions for the 
visualization of the primary anti PD-L1 antibody.
The CD61 stained tissue slides were examined by 
a board certified histopathologist (JRI) using Olympus 
BX50 microscope (Olympus, Hamburg, Germany). The 
percentage of positive stained tumor cells and the area of 
positive tumor immune cells were evaluated for each slide.
Statistical analysis
Statistical analyses were performed with GraphPad 
Prism Version 7.0f. Data are presented as symbols, each 
symbol representing individual donors. The mean and 
standard deviation (SD) is shown when three or less, 
or mean and standard error (SEM) when four or more 
biological replicates are represented. The differences 
between groups were determined after testing for Gaussian 
distribution (normality tests), and applying parametric (T 
test), or non-parametric 1-way Anova, Tukey’s multiple 
comparisons test: p < 0.05 (*), p < 0.01 (**), and p < 
0.001 (***). Additional statistical details are given in the 
respective figure legends, when appropriate.
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